Skip to content

Released Mar 13, 2014, after the close

10-K filed Mar 13, 2014, 72 days after period end · 0001144204-14-015468

Q4 2013 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$10.89MderivedN/M vs Q4 2012N/M vs Q3 2013
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived-$6,515,000N/M
Operating Incomederived-$17,095,000N/M
Operating Cash Flowderived-$4,742,000N/M
Free Cash Flowderived-$4,964,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2013derived from reported figuresQ4 2012derived from reported figuresQ4 2011derived from reported figuresQ4 2010derived from reported figures
Revenue—$1.17M$2.36M—
Net Income-$10.89M-$9.88M-$8.91M—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR